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turned; 90% of these companies were firms with more
than 100 full-time employees. Of the respondents, 67%
currently have a department or unit whose sole responsi-
bility is HE, up from 12% reported in a previous study
for 1995. The application of HE information by Cana-
dian pharmaceutical companies is most often for provin-
cial formulary submissions (100%), marketing (86%)
and pricing (81%). It is also used by 62% of respondents
for internal training and medical education programs.
Relatively few Canadian companies apply HE informa-
tion to managed care decision-making (38%) and patient
education (24%). Health economic research data was
published by 3/4 of the respondents in the form of scien-
tific posters or conference presentations and by 2/3 in the
biomedical, peer-reviewed literature. Ninety percent of
respondents cited plans for new HE studies in Canada
within the next year. CONCLUSION: Canadian compa-
nies have expanded their use of HE data in recent years.
The focus has shifted from preferential internal use (pric-
ing and marketing) to more external purposes such as
provincial and hospital formulary submissions. Health
economic research data also find a place in training
within pharmaceutical companies and in medical educa-
tion.
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OBJECTIVES: The use of formulary system can ensure
high quality and control cost if the formulary decision is
based on appropriate clinical and economic consider-
ations. We explored use of pharmacoeconomic data in
hospitals for formulary decisions. METHODS: Study de-
sign was cross-sectional telephone survey using a struc-
tured survey instrument. Participants were pharmacists
who are P&T committee members of Florida hospitals.
RESULTS: Data were collected from 73 hospitals. Most
hospitals make formulary decisions at the local level
(82%). Thirty-three percent indicate that pharmacoeco-
nomic data is used “all the time” when formulary deci-
sions are made with only six percent stating that it is
rarely or never used. Pharmacoeconomic data is rated by
62% of participants to be “very important” in formulary
decisions. The usual sources of pharmacoeconomic data
listed by participants are in-house data (73%), published
literature (55%), and pharmaceutical industry studies
(15%). When asked to rank order 10 criteria in making
formulary decisions, the mean ratings of participants sug-
gested the following order of importance: Efficacy, Tox-
icity, Side Effects, Acquisition Cost, Costs weighed by
Benefits, Extent of Drug Monitoring, Availability of Oral
Therapy, In-house data, Average Hospital LOS, Avoiding
use of Home Infusion. Most participants reported that
someone with pharmacoeconomic skills is employed by
the hospital (one has a Masters degree, one has residency
training, 31 with practical experience and 15 have infor-
mal training). Based on a pharmacoeconomic case study
comparing a new drug B to a current drug A, most of the
participants would add drug B to the formulary if it is a
new class of drug with no pre-existing resistance, has the
advantage of reduced IV use, or has a consistent reduc-
tion in hospital LOS. CONCLUSIONS: Results of this
study confirms that most hospitals consider pharmaco-
economic data invaluable in formulary decisions.
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OBJECTIVES: This analysis compares the characteristics
and processes of technology assessment (TA) in large
medical groups and HMOs. METHODS: The survey
populations were large medical groups and large HMOs
(at financial risk for lives 100,000). Mail and telephone
questionnaires were implemented. RESULTS: Survey re-
sponse rate among medical groups was 54% (39/73). Re-
sponse rate among HMOs was 43% (41/96). In respond-
ing medical groups, TA involves physicians (100%),
finance staff (85%), and quality improvement staff
(77%). In responding HMOs, medical functions (91%)
and pharmacy functions (83%) participate in TA. Medi-
cal groups most frequently conduct TA when technology
is adopted into clinical practice (88% of respondents)
and use TA to help develop guidelines (84%). HMOs
conduct TA throughout the product lifecycle and use TA
for coverage determinations. Medical groups and HMOs
conduct TA on injectable biotechnology products more
than any other type of drug. 44% of medical group re-
spondents and 90% of HMO respondents seek outside
assistance for TA, with the Agency for Health care Re-
search and Quality (AHRQ) as a leading source for med-
ical groups and private TA vendors as leading sources for
HMOs. Both medical groups and HMOs consider expert
opinion and peer-reviewed journals as the most valuable
information sources. CONCLUSIONS: The need to man-
age legal and financial risk while focusing on clinical
practice and patient care drives TA in medical groups. A
need to define legally defensible benefits drives TA in
HMOs.
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